Labor costs and payer rates are squeezing providers’ margins

The latest stories trending on MedCity News.

Editor's Pick

Top Story Labor Costs and Payer Rates Are Still Squeezing Providers' Margins New research found that most healthcare CFOs anticipate minimal financial gains this year due to high labor costs and insufficient payer rates. While providers are leveraging more data to improve financial planning, persistent challenges like wage pressures, recruiting difficulties and payers' increasing use of technology to deny claims continue to strain margins. Sponsored Tackling Messy Provider Data with an NPI-Forward Approach. Presented by ProviderTrust and MedCity News Mike Wirth, Chief Commercial Officer at ProviderTrust shares what makes provider data such a headache for payers. So much data is siloed, they were never designed to solve integration issues. The company's goal is to make credentialing easier for practitioners. Learn more. Chelsea Vane, VP of Product Management at GE Healthcare will be Speaking at INVEST 2025! Chelsea will be part of the panel: "How is AI Reshaping the Life Sciences?". You will hear from leaders in the medtech and pharma world on how AI can have an impact on everything from disease management to drug development and AI. Register For INVEST Chicago Now & Save $345

Featured News

Building Solid Relationships with Universities Critical for Early Stage Medtech Investors In a Q&A Jenni Le, a principal and investor with Venture Investors Health Fund, and INVEST Pitch Perfect judge, talked about early-stage medtech startups. Humana Taps Thyme Care for Value-Based Oncology Care Some Humana members can now access Thyme Care's cancer care services, which include 24/7 virtual care navigation. The Vibe at ViVE: Health Tech Leaders Share Insights from AI to Value-based Care [Sponsored] Executives from TailorCare, Altera Digital Health, and WiPro shared insights at the ViVE 2025 conference in Nashville. Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma Med in Pivotal Testing Eikon Therapeutics' lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also developing PARP inhibitors that could have advantages over cancer drugs currently available from this class. Radiopharmaceutical Manufacturing: A High-Stakes Race Against Time From the executive boardrooms of pharma companies to academic research centers, one fact is becoming unmistakably clear: making radiopharmaceuticals is an inherently complex, high-stakes endeavor, and the industry is racing to manage the risks of these perishable therapies before the clock runs out The Role of Medication Delivery in Non-Adherence For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.

Resources

sponsored New for 2025 EMR Software Pricing Guide Presented by MedCity News Make sure you're prepared for 2025 by knowing what to budget for EMR software. Our comprehensive pricing guide helps you compare the cost of top-rated EMR software solutions and offers insights too.   Gain Access Now

MedCity News • PO Box 901 • New York, NY unsubscribe